导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.69% | 2870/4773 |
| 近一周 | -1.22% | 1836/5465 |
| 近一月 | -1.05% | 1007/5421 |
| 近一季 | 0.16% | 973/5231 |
| 近半年 | 0.23% | 1340/4920 |
| 近一年 | 1.86% | 2402/4394 |
| 近两年 | 37.23% | 2024/2954 |
| 近三年 | 24.92% | 1312/2253 |
| 成立以来 | 41.79% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.80% 3946/4961 |
7.29% 2729/5312 |
- - |
- - |
| 2025 | 16.04% 2493/4813 |
-0.45% 2258/3635 |
2.89% 1284/4076 |
10.80% 3243/4524 |
2.25% 1029/4813 |
| 2024 | 17.43% 689/3463 |
3.52% 552/2808 |
-0.01% 668/3014 |
16.05% 1553/3129 |
-2.25% 2012/3463 |
| 2023 | -8.07% 979/2656 |
0.85% 1683/2280 |
-4.17% 1077/2385 |
1.73% 283/2515 |
-6.49% 1803/2655 |
| 2022 | -16.22% 461/2207 |
-11.02% 473/1919 |
6.25% 742/2016 |
-12.73% 772/2113 |
1.55% 1226/2208 |
| 2021 | -6.58% 1013/1822 |
-2.51% 659/1255 |
0.50% 1098/1330 |
-6.62% 968/1466 |
2.11% 698/1822 |
| 2020 | 24.79% 629/1250 |
-10.50% 784/1028 |
10.55% 763/1067 |
12.08% 406/1164 |
12.54% 456/1184 |
| 2019 | 34.86% 389/1092 |
21.86% 589/754 |
4.26% 35/804 |
0.61% 503/850 |
5.50% 712/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.49% 301/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时上证50ETF联接C VS. 长安沪深300非周期A(740101) |